Domov › Myelodysplastické syndrómy › Texas
Klinické štúdie Myelodysplastické syndrómy v štáte Texas
44 štúdií pre Myelodysplastické syndrómy hľadá účastníkov v zariadeniach v štáte Texas.
Mestá v štáte Texas
Oficiálny text štúdie (anglicky)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- University of Texas MD Anderson Cancer Center, Houston
Prebieha náborFáza 1
Vek 12 až 78 · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT03802695MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT05564390A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- MD Anderson Cancer Center, Houston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06548230Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT03661307Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- MD Anderson, Houston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT05320198A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- World Research Link, Baytown
- Texas Oncology - Denton, Denton
- The Center for Cancer and Blood Disorders, Fort Worth
- a 3 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 9. 2026 · NCT07422480Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- M D Anderson Cancer Center, Houston
Prebieha náborFáza 1
Vek 1 a viac · Všetky pohlavia · Aktualizované 18. 9. 2026 · NCT03630991Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- M D Anderson Cancer Center, Houston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT03471260Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- M D Anderson Cancer Center, Houston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT03683433A Study of BGB-11417 in Participants With Myeloid Malignancies
- Md Anderson Cancer Center, Houston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT04771130A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
- MD Anderson Cancer Center, Houston
Prebieha náborFáza 2Vítaní zdravých dobrovoľníkov
Vek 18 a viac · Všetky pohlavia · Aktualizované 11. 9. 2026 · NCT06566742A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
- The University of Texas MD Anderson Cancer Center, Houston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 11. 9. 2026 · NCT06616636ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 9. 2026 · NCT05010122Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- University of Texas UT Southwestern Comprehensive Cancer Center, Dallas
- MD Anderson Cancer Centre, Houston
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT06465953CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT04493164The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- a 10 ďalších
Prebieha náborFáza 1/2
Do veku 22 · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Texas Oncology Northeast Texas, Denison
- U.T. MD Anderson Cancer Center, Division of Cancer Medicine, Houston
- Texas Oncology Gulf Coast, The Woodlands
- a 1 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 21. 8. 2026 · NCT06499285A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
- Univ of Texas MD Anderson Cancer Center, Division of Cancer Medicine, Houston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 21. 8. 2026 · NCT04419649Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- M D Anderson Cancer Center, Houston
Prebieha náborFáza 2/3Vítaní zdravých dobrovoľníkov
Vek 18 až 70 · Všetky pohlavia · Aktualizované 11. 8. 2026 · NCT04708054Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
- University of Texas, Southwestern, Dallas
- MD Anderson Cancer Center, Houston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 10. 8. 2026 · NCT05308264Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
- M D Anderson Cancer Center, Houston
Prebieha náborFáza 1/2
Vek 12 až 80 · Všetky pohlavia · Aktualizované 7. 8. 2026 · NCT05092451Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
Prebieha náborFáza 2
Vek 15 až 80 · Všetky pohlavia · Aktualizované 30. 7. 2026 · NCT02727803Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Research Site, Houston
Prebieha náborFáza 1/2
Vek 16 a viac · Všetky pohlavia · Aktualizované 20. 7. 2026 · NCT07155226Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
- University of Texas MD Anderson Cancer Center, Houston
Prebieha náborFáza 2
Vek 60 a viac · Všetky pohlavia · Aktualizované 16. 7. 2026 · NCT01515527Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 6. 2026 · NCT01624805SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- MD Anderson Cancer Center, Houston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 6. 2026 · NCT03113643Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 15. 6. 2026 · NCT02074839A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
- M D Anderson Cancer Center, Houston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 6. 2026 · NCT05365035A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
- GSK Investigational Site, Houston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 6. 2026 · NCT06847867Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
- MD Anderson, Houston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 5. 2026 · NCT04953897Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
- MD Anderson, Houston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 5. 2026 · NCT04953910A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
- M D Anderson Cancer Center, Houston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 20. 5. 2026 · NCT04239157Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- M D Anderson Cancer Center, Houston
Prebieha náborFáza 2
Vek 18 až 65 · Všetky pohlavia · Aktualizované 20. 5. 2026 · NCT02115295A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 4. 2026 · NCT04256317A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- The University of Texas MD Anderson Cancer Center, Houston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 13. 4. 2026 · NCT05732103Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
- MD Anderson Cancer Center, Houston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 3. 2026 · NCT07107126A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- MDACC, Houston
Prebieha náborFáza 1/2
Vek 12 a viac · Všetky pohlavia · Aktualizované 24. 3. 2026 · NCT04988555Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
- Mays Cancer Center at UT Health San Antonio, San Antonio
Prebieha nábor
Vek 18 a viac · Všetky pohlavia · Aktualizované 20. 2. 2026 · NCT05745285CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- MD Anderson, Houston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 16. 1. 2026 · NCT05143996Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
- M.D. Anderson Cancer Center, Department of Leukemia, Houston
Prebieha náborFáza 1Vítaní zdravých dobrovoľníkov
Vek 18 a viac · Všetky pohlavia · Aktualizované 10. 11. 2025 · NCT05986240Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.